HC Wainwright Reiterates “$5.00” Price Target for Genocea Biosciences (GNCA)

HC Wainwright set a $5.00 target price on Genocea Biosciences (NASDAQ:GNCA) in a research note released on Wednesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research cut Genocea Biosciences from a hold rating to a sell rating in a research note on Wednesday, July 11th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $3.35.

GNCA traded up $0.02 on Wednesday, reaching $0.74. The company’s stock had a trading volume of 16,428 shares, compared to its average volume of 224,545. The company has a quick ratio of 4.01, a current ratio of 4.01 and a debt-to-equity ratio of 1.91. Genocea Biosciences has a fifty-two week low of $0.49 and a fifty-two week high of $1.39. The company has a market capitalization of $63.37 million, a price-to-earnings ratio of -0.37 and a beta of 1.14.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.09) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.10) by $0.01. On average, equities analysts anticipate that Genocea Biosciences will post -0.45 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. purchased a new position in Genocea Biosciences in the first quarter valued at about $177,000. Northern Trust Corp lifted its holdings in Genocea Biosciences by 164.5% in the first quarter. Northern Trust Corp now owns 792,677 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 492,961 shares during the period. BlackRock Inc. lifted its holdings in Genocea Biosciences by 169.1% in the first quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock valued at $4,159,000 after buying an additional 2,488,540 shares during the period. California State Teachers Retirement System lifted its holdings in Genocea Biosciences by 166.6% in the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 78,469 shares during the period. Finally, LMR Partners LLP acquired a new position in shares of Genocea Biosciences during the second quarter valued at about $175,000. Institutional investors own 60.23% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Story: How is inflation measured?

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply